<DOC>
	<DOCNO>NCT02332031</DOCNO>
	<brief_summary>To evaluate effect levothyroxine absorption , distribution , metabolization elimination sorafenib safety healthy male subject</brief_summary>
	<brief_title>Sorafenib Drug Drug Interaction Study Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Healthy male subject age 18 ( inclusive ) 45 year ( inclusive ) first screen visit . Body mass index ( BMI ) 18.5 ( inclusive ) 30.0 kg / m² ( inclusive ) body weight ≥ 65kg . Normal thyroid function indicate thyroid examination include total free T3 ( Triiodothyronine ) , T4 ( total free Thyroxine , levothyroxine ) , TSH ( Thyroid stimulate hormone ) , antiTSHreceptor ( antiTSHR ) antibody , antithyroperoxidase ( antiTPO ) antibody , antithyroglobulin antibody ( antiATA ) well thyroid ultrasound . History clinically significant metabolic , renal , hepatic , central nervous system disorder seizure , psychosis sleep disorder . History cardiovascular disease include arrhythmia , hypertension , ischemia , etc . Known suspect cardiovascular disease include potential risk atrioventricular ( AV ) block , arrhythmia , etc . without formal cardiologist consultation . Subjects received iodine contain contrast medium within 2 month first study drug administration . Use systemic topical medicine substance might affect study drug ( ) must avoid</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Sorafenib , levothyroxine , drug interaction , pharmacokinetics , healthy volunteer</keyword>
</DOC>